Ajanta Pharma Limited
AJANTPHARM
Rangering i aksjer
#3727
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited... Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Aksjekurs
$35.98
Markedsverdi
$4.50B
Endring (1 dag)
-1.18%
Endring (1 år)
29.38%
Land
IN
Handel Ajanta Pharma Limited (AJANTPHARM)
Kategori
Healthcare
Inntekter for Ajanta Pharma Limited (AJANTPHARM)
Inntekter i Jun 2026 TTM: $637.45M
Ifølge de nyeste økonomiske rapportene til Ajanta Pharma Limited er selskapets nåværende inntekter (TTM) $637.45M. I 2024 hadde selskapet inntekter på $504.74M en økning sammenlignet med inntektene i 2023, som var $455.42M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Ajanta Pharma Limited fra 2005 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $637.45M | 17.29% |
| 2025 | $543.47M | 7.67% |
| 2024 | $504.74M | 10.83% |
| 2023 | $455.42M | 5.26% |
| 2022 | $432.64M | 11.24% |
| 2021 | $388.92M | 14.37% |
| 2020 | $340.05M | 17.10% |
| 2019 | $290.39M | -8.20% |
| 2018 | $316.32M | 7.04% |
| 2017 | $295.52M | 14.66% |
| 2016 | $257.74M | 10.53% |
| 2015 | $233.19M | 18.34% |
| 2014 | $197.05M | 16.14% |
| 2013 | $169.67M | 27.01% |
| 2012 | $133.59M | 17.92% |
| 2011 | $113.29M | 24.79% |
| 2010 | $90.78M | 31.92% |
| 2009 | $68.81M | -10.99% |
| 2008 | $77.31M | 29.89% |
| 2007 | $59.52M | 15.41% |
| 2006 | $51.57M | 13.41% |
| 2005 | $45.48M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 937.20% |
IN
|
